PDCD1 and neoplasm: Of all the treatment groups, anti-PD-1 in combination with HH044 significantly extended the median survival from 43 days in the control group to 176.5 days (Figure 6, p < 0.05), with half of the group being tumor-free up to 230 days after inoculation (5/10).